[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2006135121A - Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции - Google Patents

Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции Download PDF

Info

Publication number
RU2006135121A
RU2006135121A RU2006135121/13A RU2006135121A RU2006135121A RU 2006135121 A RU2006135121 A RU 2006135121A RU 2006135121/13 A RU2006135121/13 A RU 2006135121/13A RU 2006135121 A RU2006135121 A RU 2006135121A RU 2006135121 A RU2006135121 A RU 2006135121A
Authority
RU
Russia
Prior art keywords
antigen
vaccine composition
type
sterol
composition according
Prior art date
Application number
RU2006135121/13A
Other languages
English (en)
Other versions
RU2347586C2 (ru
Inventor
Пол Джозеф ДОМИНОВСКИ (US)
Пол Джозеф Доминовски
Памела Кей КЛОУЗ (US)
Памела Кей КЛОУЗ
Ричард Ли КРЕБС (US)
Ричард Ли КРЕБС
Рамасами Маннар МАННАН (US)
Рамасами Маннар МАННАН
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2006135121(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2006135121A publication Critical patent/RU2006135121A/ru
Application granted granted Critical
Publication of RU2347586C2 publication Critical patent/RU2347586C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Вакцина, содержащая гликозид сапонина, стерин и антиген, где указанный гликозид сапонина и указанный стерин ассоциируют друг с другом с образованием комплексов в форме спиралевидных мицелл, и где указанный антиген смешан c указанными спиралевидными мицеллами, но не включен в их состав.2. Вакцинная композиция по п.1, дополнительно содержащая приемлемый в ветеринарии носитель.3. Вакцинная композиция по п.2, где указанный приемлемый в ветеринарии носитель представляет собой эмульсию типа "масло в воде".4. Вакцинная композиция по п.1, где указанный гликозид сапонина представляет собой тритерпеноид.5. Вакцинная композиция по п.4, где указанный тритерпеноид представляет собой Quil A.6. Вакцинная композиция по п.1, где указанный стерин представляет собой холестерин.7. Вакцинная композиция по п.1, где указанный антиген включает вирусный антиген, бактериальный антиген или их комбинацию.8. Вакцинная композиция по п.7, где указанный антиген включает антиген BVDV 1 типа или 2 типа.

Claims (8)

1. Вакцина, содержащая гликозид сапонина, стерин и антиген, где указанный гликозид сапонина и указанный стерин ассоциируют друг с другом с образованием комплексов в форме спиралевидных мицелл, и где указанный антиген смешан c указанными спиралевидными мицеллами, но не включен в их состав.
2. Вакцинная композиция по п.1, дополнительно содержащая приемлемый в ветеринарии носитель.
3. Вакцинная композиция по п.2, где указанный приемлемый в ветеринарии носитель представляет собой эмульсию типа "масло в воде".
4. Вакцинная композиция по п.1, где указанный гликозид сапонина представляет собой тритерпеноид.
5. Вакцинная композиция по п.4, где указанный тритерпеноид представляет собой Quil A.
6. Вакцинная композиция по п.1, где указанный стерин представляет собой холестерин.
7. Вакцинная композиция по п.1, где указанный антиген включает вирусный антиген, бактериальный антиген или их комбинацию.
8. Вакцинная композиция по п.7, где указанный антиген включает антиген BVDV 1 типа или 2 типа.
RU2006135121A 2004-04-05 2005-03-24 Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции RU2347586C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55967704P 2004-04-05 2004-04-05
US60/559,677 2004-04-05

Publications (2)

Publication Number Publication Date
RU2006135121A true RU2006135121A (ru) 2008-04-10
RU2347586C2 RU2347586C2 (ru) 2009-02-27

Family

ID=34961993

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006135121A RU2347586C2 (ru) 2004-04-05 2005-03-24 Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции

Country Status (23)

Country Link
US (1) US7122191B2 (ru)
EP (2) EP1742659B1 (ru)
JP (2) JP5393978B2 (ru)
KR (5) KR101143060B1 (ru)
CN (1) CN1997390B (ru)
AR (1) AR048822A1 (ru)
AU (1) AU2005230708B2 (ru)
BR (1) BRPI0509606B1 (ru)
CA (1) CA2561914C (ru)
DK (1) DK1742659T3 (ru)
ES (1) ES2409782T3 (ru)
HK (1) HK1108830A1 (ru)
NO (1) NO341034B1 (ru)
NZ (1) NZ550152A (ru)
PL (1) PL1742659T3 (ru)
PT (1) PT1742659E (ru)
RU (1) RU2347586C2 (ru)
SI (1) SI1742659T1 (ru)
TW (1) TWI301067B (ru)
UA (1) UA89631C2 (ru)
UY (1) UY28840A1 (ru)
WO (1) WO2005097181A1 (ru)
ZA (1) ZA200608200B (ru)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
EP1333858B8 (en) * 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AR044732A1 (es) * 2002-11-08 2005-10-05 H P B S A Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
KR101143060B1 (ko) * 2004-04-05 2012-05-08 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
CA2612980C (en) 2005-06-27 2019-01-15 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising a haemophilus influenzae type b saccharide conjugate
WO2007022425A2 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP1792619A1 (en) * 2005-11-28 2007-06-06 Laboratorios Maymo, S.A. Beta-sitosterol for treating porcine respiratory disease complex
EA015271B1 (ru) 2006-01-27 2011-06-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EP1988918A4 (en) * 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
PL2200642T3 (pl) 2007-10-19 2012-09-28 Novartis Ag Preparaty szczepionek meningokokowych
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
CN102137675A (zh) 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
AU2012258478B2 (en) * 2008-06-27 2013-10-03 Zoetis Services Llc Novel adjuvant compositions
EP2331127A2 (en) 2008-09-18 2011-06-15 Novartis AG Vaccine adjuvant combinations
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
AU2010252661B2 (en) 2009-05-29 2013-08-22 Novartis Ag Assays for influenza virus hemagglutinins
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
US9878036B2 (en) * 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
EA023811B1 (ru) 2009-10-20 2016-07-29 Новартис Аг Способ получения вируса с использованием конструкции, кодирующей вирусную рнк
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2496255A4 (en) * 2009-11-05 2014-03-26 Mercia Pharma Inc ADJUVATED INFLUENZA VACCINE IN NANOPARTICLE FORM
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
DE102009056884B4 (de) * 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
SI2506834T1 (sl) 2009-12-03 2016-04-29 Novartis Ag Cirkulacija sestavin med homogenizacijo in mikrofluidizacijo emulzij
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
WO2011067669A2 (en) 2009-12-03 2011-06-09 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN101926994B (zh) * 2010-08-19 2012-10-10 中国医学科学院医学生物学研究所 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
TR201908715T4 (tr) 2011-01-26 2019-07-22 Glaxosmithkline Biologicals Sa Rsv immünizasyon rejimi.
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
ES2732708T3 (es) 2011-09-14 2019-11-25 Glaxosmithkline Biologicals Sa Procedimientos de fabricación de glucoconjugados de sacárido-proteína
CA2850857C (en) 2011-10-06 2022-07-26 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
JP2014532620A (ja) 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
JP2015500864A (ja) 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
DK2890394T3 (da) 2012-08-31 2019-07-15 Glaxosmithkline Biologicals Sa Stabiliserede proteiner til immunisering mod Staphylococcus aureus
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
CN104602702B (zh) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 外膜囊泡
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
AR092939A1 (es) 2012-10-09 2015-05-06 Univ Gent Vacuna contra cooperia
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
SI2925355T1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals S.A. Antigens and combinations of Pseudomonas antigens
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
EP2968512A2 (en) 2013-03-13 2016-01-20 Novartis AG Influenza b virus reassortment
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
MX2015016755A (es) 2013-06-06 2016-04-13 Novartis Ag Reagrupamiento del virus de influenza.
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
CA2927224A1 (en) 2013-10-17 2015-04-23 Zoetis Services Llc Methods and compositions for treatment of s. equi infection
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CN115154596A (zh) * 2013-11-26 2022-10-11 硕腾服务有限责任公司 诱导免疫应答的组合物
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
DK3122378T3 (da) 2014-03-26 2020-03-02 Glaxosmithkline Biologicals Sa Mutante stafylokokantigener
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
CN107106674A (zh) * 2015-01-16 2017-08-29 硕腾服务有限责任公司 口蹄疫疫苗
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP6907227B2 (ja) * 2016-03-23 2021-07-21 インターベット インターナショナル ベー． フェー． Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン
WO2017196979A1 (en) * 2016-05-10 2017-11-16 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
EP3454893A4 (en) * 2016-05-11 2020-01-01 Phibro Animal Health Corporation COMPOSITION WITH ANTIGENS AND A MUCUTINE ADJUVAN AND METHOD FOR USE
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
EP3914708A1 (en) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023154960A1 (en) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
UA56132C2 (ru) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) * 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE60017211T2 (de) * 1999-02-17 2005-06-02 Pfizer Products Inc., Groton Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
DE10106446A1 (de) 2001-02-09 2002-10-10 Haarmann & Reimer Gmbh Verfahren zur Herstellung blauer Mikrokapseln
NZ538394A (en) * 2002-08-26 2008-06-30 Pfizer Prod Inc Vaccine for respiratory and reproductive system infections in cattles
ES2303046T3 (es) * 2003-01-29 2008-08-01 Pfizer Products Inc. Vacunas caninas contra bordetella bronchiseptica.
CA2521051C (en) * 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
KR101143060B1 (ko) * 2004-04-05 2012-05-08 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물

Also Published As

Publication number Publication date
BRPI0509606B1 (pt) 2019-01-15
UA89631C2 (en) 2010-02-25
KR20080073376A (ko) 2008-08-08
ES2409782T3 (es) 2013-06-27
KR20090007497A (ko) 2009-01-16
US20050220814A1 (en) 2005-10-06
US7122191B2 (en) 2006-10-17
TW200600108A (en) 2006-01-01
UY28840A1 (es) 2005-11-30
PL1742659T3 (pl) 2013-08-30
NO341034B1 (no) 2017-08-07
PT1742659E (pt) 2013-06-03
JP2011168605A (ja) 2011-09-01
CN1997390A (zh) 2007-07-11
TWI301067B (en) 2008-09-21
CA2561914A1 (en) 2005-10-20
AR048822A1 (es) 2006-05-31
KR20090051129A (ko) 2009-05-20
EP1742659B1 (en) 2013-03-13
SI1742659T1 (sl) 2013-07-31
CA2561914C (en) 2013-09-10
AU2005230708B2 (en) 2009-01-15
AU2005230708A1 (en) 2005-10-20
DK1742659T3 (da) 2013-06-03
NO20065039L (no) 2006-11-02
RU2347586C2 (ru) 2009-02-27
NZ550152A (en) 2009-04-30
EP2269644A3 (en) 2012-10-17
KR20070008625A (ko) 2007-01-17
JP5393978B2 (ja) 2014-01-22
KR20110132416A (ko) 2011-12-07
JP2007531790A (ja) 2007-11-08
BRPI0509606A (pt) 2007-09-18
KR101143060B1 (ko) 2012-05-08
ZA200608200B (en) 2008-09-25
EP1742659A1 (en) 2007-01-17
WO2005097181A1 (en) 2005-10-20
HK1108830A1 (en) 2008-05-23
CN1997390B (zh) 2012-10-10
EP2269644A2 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
RU2006135121A (ru) Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
Boccon-Gibod Radical prostatectomy: open? laparoscopic? robotic?
Gebauer et al. Hepatic involvement in listeriosis
BRPI0407586A (pt) composições contendo um componente polissacarìdeo definido
Al‐Qubati et al. Dermatologists combat leprosy in Yemen
Pender Recurrent obstruction of an obturator hernia
JPH06321744A (ja) 口腔用組成物
Castellani Microbe hunters
Edwards Anatomy for Surgeons, vol 2: The Thorax, Abdomen, and Pelvis
GB1035701A (en) Emulsions suitable for use as adjuvants for immunological agents
JUL mn-unicationi froml Professor Putti. Sir Squire Sprigge
Belicza et al. Pub lic Health Re forms and De vel op ment of Health Ser vice in the Ðakovo Sub-dis trict and Ad min is tra tive County in the Pe riod 1850-1899
Suntzeff et al. Response of a transplantable rhabdomyosarcoma to cyclophosphamide therapy with special reference to differences in male and female mice
Weinzirl The Science of Bacteriology in the State of Washington
Stimson PRESCRIPTION OF SULFONAMIDES
Perimenis et al. Unusual echinococcal cyst
Gebauer et al. Postanesthetic Encephalopathy Following Cyclopropane
CHARLES Secretary.
SHIMADA Anatomical knowledge for radical neck dissection
GGGGGGGCCS DoUGLAs GUTHRIE. Lord Lister, His Life and Doctrine. Baltimore: The Wil-liams and Wilkins Co., 1949. viii--128 pp. Ill. $3.50. The author of A History of Medicine, published in 1937, has enlarged chapters 16 and 17 of that work into a book on Lord Lister. He has published for the first time, through the courtesy of the University of Edinburgh and the Royal College of
Donohue WHEN CHRISTMAS CAME AGAIN
Teytelbaum Doctora
Hess AN ANTISEPTIC HÆMOSTATIC.
EA200501367A1 (ru) Вакцинная композиция на основе ганглиозидов для подкожного введения
Isaacs HEMOGLOBIN-RED BLOOD CELL RATIO-Reply

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20150127

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20150918

PD4A Correction of name of patent owner